Advertisement
Canada markets closed
  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     
  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     
  • DOW

    37,775.38
    +22.07 (+0.06%)
     
  • CAD/USD

    0.7255
    -0.0008 (-0.11%)
     
  • CRUDE OIL

    85.90
    +3.17 (+3.83%)
     
  • Bitcoin CAD

    84,551.16
    -770.04 (-0.90%)
     
  • CMC Crypto 200

    1,243.70
    +358.16 (+37.57%)
     
  • GOLD FUTURES

    2,418.50
    +20.50 (+0.85%)
     
  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     
  • 10-Yr Bond

    4.6470
    +0.0620 (+1.35%)
     
  • NASDAQ futures

    17,278.00
    -269.25 (-1.53%)
     
  • VOLATILITY

    18.00
    -0.21 (-1.15%)
     
  • FTSE

    7,877.05
    +29.06 (+0.37%)
     
  • NIKKEI 225

    36,818.81
    -1,260.89 (-3.31%)
     
  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     

How Gilead Sciences plans to Beat Merck in Hepatitis C

Merck's Zepatier poses a new challenge to its best selling drug, but the risk might not be as big as you think.

This podcast was recorded on Feb. 3, 2016.